ReviewMaterials today. Bio2025
Nanomedicine for chronic pain management: From pathophysiology to engineered drug delivery systems.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in epigenetic regulation of potassium channels in chronic pain.Molecular biology reports · 2026Review
- Targeting Microglia-Neuron Crosstalk to Regulate Neuronal Excitability: Novel Translational Approaches for Chronic Pain Intervention.International journal of molecular sciences · 2026Review
- Acupotomy for Cervical Spondylosis-Related Neck Pain: A Study Protocol for a Randomized Controlled Trial.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain represents a significant burden on individuals and society, impacting financial costs, emotional well-being, and productivity. Traditional treatments for chronic pain, such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and local anesthetics, are commonly used but have notable limitations. Opioids carry a risk of addiction, NSAIDs pose gastrointestinal and cardiovascular risks, and the short duration of analgesic effects from single doses of local anesthetics limits their effectiveness in long-term pain management. This review aims to provide a comprehensive resource for researchers exploring innovative approaches to chronic pain treatment, with a particular focus on drug delivery systems. It delves into the classification of chronic pain, its underlying mechanisms, and the most commonly used pharmacological treatments, while critically evaluating the limitations of each strategy. Furthermore, the review highlights recent advancements in drug delivery technologies for chronic pain management, discussing both the potential opportunities and challenges of translating these innovations into clinical practice. Ultimately, the review identifies existing challenges in the field and outlines promising research directions for the future development of more effective drug delivery strategies in chronic pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.